Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Kalvista Pharmaceuticals, Ltd.

Clinical trials sponsored by Kalvista Pharmaceuticals, Ltd., explained in plain language.

KalVista Pharmaceuticals KALV NASDAQ

A pharmaceutical company developing oral therapies for hereditary angioedema and other diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 1 Not yet recruiting 1 Completed 4 Terminated 1

New hope for kids with rare swelling disorder: early access drug offered

Disease control AVAILABLE

This program provides early access to an investigational drug called sebetralstat for children aged 2 to 11 with hereditary angioedema (HAE), a condition causing sudden, painful swelling. The drug is taken at the start of an attack to reduce symptoms. It is available to children …

Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Disease control

Last updated Jul 25, 2026 00:00 UTC